BPTH - Bio-Path Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2415
-0.0321 (-11.73%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.2736
Open0.2820
Bid0.0000 x 2900
Ask0.0000 x 1300
Day's Range0.2100 - 0.2820
52 Week Range0.2100 - 3.0900
Volume242,237
Avg. Volume319,674
Market Cap3.285M
Beta (3Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)-0.7850
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that previously announced interim data from the Company’s Phase 2 study evaluating prexigebersen as a treatment for acute myeloid leukemia (AML) were presented in a poster at the 2018 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 1-4, 2018 in San Diego, CA. Prexigebersen was safely administered to patients with untreated AML, who were considered unsuitable for standard chemotherapy.

  • Benzinga18 days ago

    The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

    Notwithstanding the scanty news flow, biotech stocks came under intense selling pressure last week, pushing the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) further into the red. Here's a list of ...

  • Associated Press28 days ago

    Bio-Path: 3Q Earnings Snapshot

    On a per-share basis, the Bellaire, Texas-based company said it had a loss of 27 cents. The company's shares closed at 44 cents. A year ago, they were trading at $2.97. _____ This story was generated by ...

  • GlobeNewswire28 days ago

    Bio-Path Holdings Reports Third Quarter 2018 Financial Results

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2018 and provided an update on recent corporate developments. “Throughout the third quarter, we continued to make meaningful progress advancing and expanding our robust clinical development pipeline of RNAi nanoparticle drugs to bring innovative new treatments to cancer patients with high unmet medical need,” stated Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.  “Most recently, we were delighted to report that interim data from our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia (AML) were accepted for poster presentation at the upcoming American Society of Hematology Annual Meeting (ASH) taking place in early December 2018.

  • GlobeNewswirelast month

    Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

    HOUSTON, Nov. 08, 2018 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to.

  • GlobeNewswirelast month

    Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting

    HOUSTON, Nov. 01, 2018 -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to.

  • Simply Wall St.2 months ago

    What does Bio-Path Holdings Inc’s (NASDAQ:BPTH) Balance Sheet Tell Us About Its Future?

    The direct benefit for Bio-Path Holdings Inc (NASDAQ:BPTH), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...

  • GlobeNewswire3 months ago

    Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering

    HOUSTON, Sept. 25, 2018 -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path),  a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle.

  • GlobeNewswire3 months ago

    Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

    Bio-Path will issue to the investors warrants to purchase up to 2,261,538 shares of common stock, which represents 100% of the number of shares of common stock issued in the registered direct offering, with an exercise price $0.96 per share and exercise period commencing six (6) months following the issuance date and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.

  • Associated Press4 months ago

    Bio-Path: 2Q Earnings Snapshot

    The Bellaire, Texas-based company said it had a loss of 15 cents per share. The company's shares closed at $1.41. A year ago, they were trading at $3. _____ This story was generated by Automated Insights ...

  • ACCESSWIRE4 months ago

    Bio-Path Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:30 AM Eastern ...

  • ACCESSWIRE6 months ago

    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

    DALLAS, TX / ACCESSWIRE / June 26, 2018 / Bio-Path Holdings, Inc. ("Bio-Path") (NASDAQ: BPTH): COMPANY DESCRIPTION Bio-Path Holdings, Inc. (Bio-Path) is a clinical-stage biotechnology company ...

  • With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?
    Simply Wall St.7 months ago

    With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • Associated Press7 months ago

    Bio-Path: 1Q Earnings Snapshot

    The Bellaire, Texas-based company said it had a loss of 17 cents per share. The company's shares closed at $1.76. A year ago, they were trading at $5.31. _____ This story was generated by Automated Insights ...

  • ACCESSWIRE8 months ago

    Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis

    Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...

  • Bio-Path Leukemia Combo Study Shows Positive Early Data
    Zacks8 months ago

    Bio-Path Leukemia Combo Study Shows Positive Early Data

    Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.